RETEVMO 40 mg/1
selpercatinib · TABLET, COATED · Eli Lilly and Company
Retevmo (selpercatinib) is an oral kinase inhibitor tablet used to treat certain cancers caused by RET gene mutations or fusions, including medullary thyroid cancer and non-small cell lung cancer. This prescription medication works by blocking the RET protein that helps cancer cells grow and spread.
Key Facts
- Brand Name
- RETEVMO
- Generic Name
- selpercatinib
- NDC Code (Product)
0002-5340- Manufacturer
- Eli Lilly and Company
- Strength
- 40 mg/1
- Dosage Form
- TABLET, COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA218160
- Drug Class
- Kinase Inhibitor [EPC]
- Marketing Start
- 04/10/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is RETEVMO used for?
Retevmo (selpercatinib) is an oral kinase inhibitor tablet used to treat certain cancers caused by RET gene mutations or fusions, including medullary thyroid cancer and non-small cell lung cancer. This prescription medication works by blocking the RET protein that helps cancer cells grow and spread.
Is RETEVMO a controlled substance?
RETEVMO is not classified as a controlled substance by the DEA.
What is the generic name for RETEVMO?
The generic name for RETEVMO is selpercatinib. There are no other listed brand versions of selpercatinib.
What is the NDC code for RETEVMO 40 mg/1?
The NDC (National Drug Code) for RETEVMO 40 mg/1 is 0002-5340, listed by Eli Lilly and Company.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)